Journal Watch · Frontiers in Immunology · 2026
Galectin-3 promotes FBXL5-dependent ubiquitination and degradation of YAP1 to constrain colorectal cancer growth.
Nevertheless, additional validation using TEAD reporter assays and YAP1 rescue or mutant analyses will be required to further strengthen the causal framework of this axis.
TL;DR
Nevertheless, additional validation using TEAD reporter assays and YAP1 rescue or mutant analyses will be required to further strengthen the causal framework of this axis.
Key findings
- In vivo, LGALS3 knockdown markedly increased tumor volume, whereas FBXL5 overexpression reduced tumor growth.
- YAP1 protein expression patterns were consistent with these findings.
- Cell proliferation assays and xenograft experiments further supported an antitumor effect of this signaling axis in CRC.<h4>Conclusion</h4>This study suggests that the Gal-3-FBXL5-YAP1 axis plays an important role in restraining CRC progression, expands the mechanistic understanding of Gal-3-associated tumor suppression, and supports Gal-3 as a potential therapeutic target in CRC.
- Nevertheless, additional validation using TEAD reporter assays and YAP1 rescue or mutant analyses will be required to further strengthen the causal framework of this axis.
What they did
Functional effects were further assessed using cell proliferation assays and xenograft mouse models to investigate the biological role of the Gal-3-FBXL5-YAP1 axis.<h4>Results</h4>Gal-3 positively correlated with FBXL5 and bound FBXL5 to enhance its expression. Patients with high LGALS3 and FBXL5 expression exhibited better survival. Mechanistically, FBXL5 promoted YAP1 protein degradation through the ubiquitin pathway without altering YAP1 transcript levels, suggesting a post-transcriptional regulatory mechanism. Gal-3 increased FBXL5 abundance and promoted YAP1 degradation, thereby supporting the existence of a Gal-3-FBXL5-YAP1 regulatory axis.
Full abstract (original)
Background: <h4>Introduction</h4>The molecular heterogeneity of colorectal cancer (CRC) profoundly shapes clinical outcomes and treatment response, underscoring the need to elucidate the underlying mechanisms to refine diagnosis and therapy. Although LGALS3, which encodes Galectin-3 (Gal-3), has been implicated in tumor biology, its precise role and regulatory mechanism in CRC remain incompletely understood. This study aimed to define the clinical relevance and mechanistic function of the Gal-3-related signaling axis in CRC.<h4>Methods</h4>We integrated TCGA and single-cell RNA sequencing data to evaluate the clinical significance of LGALS3 in CRC. Molecular investigations, including co-immunoprecipitation and ubiquitination assays, were performed to examine how Gal-3 regulated FBXL5 and YAP1.
What they did: Functional effects were further assessed using cell proliferation assays and xenograft mouse models to investigate the biological role of the Gal-3-FBXL5-YAP1 axis.<h4>Results</h4>Gal-3 positively correlated with FBXL5 and bound FBXL5 to enhance its expression. Patients with high LGALS3 and FBXL5 expression exhibited better survival. Mechanistically, FBXL5 promoted YAP1 protein degradation through the ubiquitin pathway without altering YAP1 transcript levels, suggesting a post-transcriptional regulatory mechanism. Gal-3 increased FBXL5 abundance and promoted YAP1 degradation, thereby supporting the existence of a Gal-3-FBXL5-YAP1 regulatory axis.
Results & conclusions: In vivo, LGALS3 knockdown markedly increased tumor volume, whereas FBXL5 overexpression reduced tumor growth. YAP1 protein expression patterns were consistent with these findings. Cell proliferation assays and xenograft experiments further supported an antitumor effect of this signaling axis in CRC.<h4>Conclusion</h4>This study suggests that the Gal-3-FBXL5-YAP1 axis plays an important role in restraining CRC progression, expands the mechanistic understanding of Gal-3-associated tumor suppression, and supports Gal-3 as a potential therapeutic target in CRC. Nevertheless, additional validation using TEAD reporter assays and YAP1 rescue or mutant analyses will be required to further strengthen the causal framework of this axis.
Abstract © the authors / Frontiers in Immunology (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.3389/fimmu.2026.1769656 · PubMed 42093989.
Why it matters for pharma & biotech
- Relevant to Immunology teams tracking Frontiers in Immunology for new targets, mechanisms and biomarkers.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- The work is preclinical. Results in animal or cell models frequently do not translate directly to human efficacy or safety.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Frontiers in Immunology study find?
Nevertheless, additional validation using TEAD reporter assays and YAP1 rescue or mutant analyses will be required to further strengthen the causal framework of this axis.
What type of study is this?
It is a preclinical (animal / model) study, published in Frontiers in Immunology in 2026. Functional effects were further assessed using cell proliferation assays and xenograft mouse models to investigate the biological role of the Gal-3-FBXL5-YAP1 axis.<h4>Results</h4>Gal-3 positively correlated with FBXL5 and bound FBXL5 to enhance its expression.
Where can I read the original paper?
The original is at the publisher via DOI 10.3389/fimmu.2026.1769656. PubMed ID: 42093989. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/galectin-3-promotes-fbxl5-dependent-ubiquitination-and-degradation-of-ya-769656/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides